Partner Nathaniel Lacktman was quoted in a Modern Healthcare article, “VA looks to ease telehealth regulations,” about a Veterans Affairs Department proposal that would allow VA providers to conduct telehealth visits with VA patients across state lines.
Currently, VA telehealth is limited by state restrictions on a doctor’s ability to see patients outside the state in which the doctor is licensed to practice.
Lacktman said the proposal, while limited to VA providers and VA patients, could be the first step towards a national medical practice licensing concept. “Overall, I predict providers will look upon this new rule favorably,” he said.
Read the full story here (subscription required).
Currently, VA telehealth is limited by state restrictions on a doctor’s ability to see patients outside the state in which the doctor is licensed to practice.
Lacktman said the proposal, while limited to VA providers and VA patients, could be the first step towards a national medical practice licensing concept. “Overall, I predict providers will look upon this new rule favorably,” he said.
Read the full story here (subscription required).
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”